About SynDevRx
Scientific Advisors

SynDevRx enjoys a close working relationship with top researchers in the fields of drug development, MetAP2 biology, oncology, and angiogenesis. We have assembled well-recognized names in the industry to provide advice and guidance on clinical trial strategy, design, indication selection, biomarker identification and end-point definition.

Bruce R. Zetter, Ph.D. - Chair

Dr. Bruce Zetter is the Charles Nowiszewski Professor of Cancer Biology, Harvard Medical School, and is highly regarded nationally and internationally as a leader in the research of tumor angiogenesis, progression, and metastasis as well as cancer diagnosis.

Dr. Zetter has won numerous national and international awards for his work in the field of cancer research including a Faculty Research Award from the American Cancer Society and the prestigious MERIT award from the US National Cancer Institute. He is also on the editorial board of eight peer-reviewed journals. He has chaired several research conferences including the Gordon Conference on Cancer considered one of America's premier cancer conferences.

Dr. Zetter serves on several grant review boards for public agencies such as the American Cancer Society. He has chaired the grant review board on breast and prostate cancer for the National Institutes of Health. He also serves as a consultant and scientific advisor to major biotechnology and pharmaceutical companies.

Daniel Von Hoff, MD

Dr. Von Hoff is Executive VP and Physician-in-Chief, Translational Genomics Research Institute (TGen) and Executive VP and Director of the Translational Drug Development Division (TD2). Dr. Von Hoff is also Clinical Professor of Medicine, University of Arizona, Department of Medicine, and he serves as Head of the Pancreatic Cancer Research Team (PCRT) and Chief Scientific Officer for US Oncology.

Dr. Von Hoff is a world-renowned expert in drug development and clinical trial design. He and his colleagues were involved in the early development of mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, CPT-11, and others. Dr. Von Hoff has published more than 500 papers, 125 book chapters, and nearly 900 scientific abstracts.

Dr. Von Hoff recently had an appointment to the National Cancer Advisory Board through March 2010. He is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He was a founder of ILEX™ Oncology, Inc. (acquired by Genzyme), and is founder and the Editor Emeritus of Investigational New Drugs - The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics.

Roy Herbst, MD, Ph.D.

Dr. Herbst is the Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven; Associate Director for Translational Research, Yale Cancer Center; Clinical Research Program Leader, Thoracic Oncology Program, Yale Cancer Center

He is a member of the American Association for Cancer Research (AACR), where he chairs the Tobacco Task Force, as well as the American Society of Clinical Oncology and the Institute of Medicine’s National Cancer Policy Forum. He is a fellow of the American College of Physicians. Dr. Herbst is also a vice chair of the Southwest Oncology Group’s lung committee, a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for the International Association for the Study of Lung Cancer. He has authored more than 200 peer-reviewed papers and has current grant funding for his work from numerous sources including the National Cancer Institute, AACR and multiple charitable foundations.

Dr. Herbst received his medical degree from Cornell University Medical College and earned a Ph.D. in molecular cell biology from Rockefeller University. He completed his medical oncology fellowship at Dana Farber Cancer Institute and a medical hematology fellowship at Brigham and Women’s Hospital in Boston, where he additionally received a master’s degree from Harvard University in their clinical investigator training program.

Rakesh Jain, Ph.D.

Dr. Jain brings unique perspective to drug development.  As a chemical and biomedical engineer, he has made significant contributions to research in the area of tumor environments. He is the Andrew Werk Professor of Tumor Biology at Harvard Medical School and serves as Director of the Edwin L. Steele Laboratory for Tumor Biology at the Massachusetts General Hospital Cancer Center In Boston. He is a leading expert on tumor pathophysiology, angiogenesis, drug delivery, and intravital microscopy. Dr. Jain has published nearly 300 scientific papers and five books on tumor blood supply and other topics. He also holds several patents for medical discoveries, such as locating tumors prior to needle biopsy and devising a new method for enhancing drug delivery.

Donald E. Ingber, M.D., Ph.D.
Dr. Ingber is Founding Director of the Wyss Institute and a leader in the emerging field of biologically inspired engineering. He oversees a multifaceted effort to identify the mechanisms that living organisms use to self assemble and to apply these design principles to develop advanced materials and devices. Don has made major contributions to cell and tissue engineering, angiogenesis and cancer research, systems biology, and nanobiotechnology. He was the first researcher to recognize that tensegrity architecture (in which a system stabilizes itself mechanically by balancing local compression with continuous tension) is a fundamental principle in the way living organisms are structured at the nanometer scale.

Dr. Ingber has authored more than 300 publications and 40 patents and has received numerous distinctions including the Pritzer Award from the Biomedical Engineering Society, Lifetime Achievement Award from the Society of In Vitro Biology, the Rous-Whipple Award from the American Society for Investigative Pathology, and the Department of Defense Breast Cancer Innovator Award. He holds the Judah Folkman Professorship of Vascular Biology at Harvard Medical School and Children's Hospital Boston and is a Professor of Bioengineering at the Harvard School of Engineering and Applied Sciences. Dr. Ingber also serves on the Board of Directors of the National Space Biomedical Research Institute and was recently elected to the College of Fellows of the American Institute for Medical and Biological Engineering.